Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease

Bibliography

• Knudsen Gerber DS. Selegiline and rasagiline: twins or distant cousins? Guidelines. Consult Pharm 2011;26(1):48-51
   PubMedGoogle Scholar
• Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use–a post-marketing observational study in patients with Parkinson's disease. Eur J Neurol 2010;17(9):1164-71
   PubMed Web of Science ®Google Scholar
• Chitnis S, Jaffery M, Dewey RB. Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease. Int J Neurosci 2012;122(1):22-5
   PubMed Web of Science ®Google Scholar
• Tarrants ML, Denarie MF, Castelli-Haley J, et al. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 2010;8(4):374-83
   PubMed Web of Science ®Google Scholar
• Levin OS, Boiko AN, Ivanov AK. Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study). Zh Nevrol Psikhiatr Im S S Korsakova 2010;110(11 Pt 2):42-7
   PubMedGoogle Scholar
• Jost WH, Klasser M, Reichmann H. Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment. Fortschr Neurol Psychiatr 2008;76(10):594-9
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;61(13):1268-78
   Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
   PubMed Web of Science ®Google Scholar
• Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006;21(5):616-23
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009;24(4):564-73
   PubMed Web of Science ®Google Scholar
• Lew MF, Hauser RA, Hurtig HI, et al. Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci 2010;120(6):404-8
   PubMed Web of Science ®Google Scholar
• White WB, Salzman P, Schwid SR. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. Hypertension 2008;52(3):587-93
   PubMed Web of Science ®Google Scholar
• Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006;66(9):1427-9
   PubMed Web of Science ®Google Scholar
• Elmer L, Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006;248(1-2):78-83
   PubMed Web of Science ®Google Scholar
• deMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006;21(10):1716-21
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol 2011;18(12):1373-8
   PubMed Web of Science ®Google Scholar
• Tolosa E, Stern MB. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. Eur J Neurol 2012;19(2):258-64
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
   PubMed Web of Science ®Google Scholar
• Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008;23(15):2194-201
   PubMed Web of Science ®Google Scholar
• Fedorova NV, Tekaeva FK, Bel'gusheva ME. The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova 2011;111(7):30-6
   Google Scholar
• Hilli J, Korhonen T, Laine K. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(8):1526-32
   PubMed Web of Science ®Google Scholar
• Goren T, Adar L, Sasson N, et al. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol 2010;50(12):1420-8
   PubMed Web of Science ®Google Scholar
• Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004;24(10):1295-305
   PubMed Web of Science ®Google Scholar
• Freedman NM, Mishani E, Krausz Y, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med 2005;46(10):1618-24
   PubMed Web of Science ®Google Scholar
• Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26(10):1851-8
   PubMed Web of Science ®Google Scholar
• Korchounov A, Winter Y, Rossy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol 2012;35(3):121-4
   PubMed Web of Science ®Google Scholar
• Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000;23(6):324-30
   PubMed Web of Science ®Google Scholar
• Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004;19(8):916-23
   PubMed Web of Science ®Google Scholar
• Wilson RE, Seeberger LC, Silver D, et al. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. Neurologist 2011;17(6):318-24
   PubMed Web of Science ®Google Scholar
• Zagmutt FJ, Tarrants ML. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci 2012;122(7):345-53
   PubMed Web of Science ®Google Scholar
• Zhang R, Spengler DC, Saint-Hilaire MH, et al. Association of adverse effects with monoamine oxidase type B inhibitor and catechol-o-methyl transferase inhibitor combination therapy in Parkinson's disease patients. Advances in Parkinson's Disease 2012;15-0
   Google Scholar